{"id":"vandetanib-sar390530","safety":{"commonSideEffects":[{"rate":"30-40%","effect":"Diarrhea"},{"rate":"20-30%","effect":"Nausea"},{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Hypertension"},{"rate":"10-20%","effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL6054362","moleculeType":null,"molecularWeight":"459.36"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by inhibiting the activity of these kinases, which are involved in the growth and spread of cancer cells. This leads to a decrease in tumor growth and angiogenesis.","oneSentence":"Vandetanib is a tyrosine kinase inhibitor that targets RET, VEGFR2, and EGFR.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:56:00.796Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Medullary thyroid cancer"}]},"trialDetails":[{"nctId":"NCT01496313","phase":"PHASE4","title":"To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-06-08","conditions":"Thyroid Cancer","enrollment":81},{"nctId":"NCT00410761","phase":"PHASE3","title":"An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-11-23","conditions":"Thyroid Cancer","enrollment":331},{"nctId":"NCT01298323","phase":"PHASE3","title":"Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-02-25","conditions":"Locally Advanced or Metastatic Medullary Thyroid Cancer, Medullary Thyroid Cancer","enrollment":205},{"nctId":"NCT00418886","phase":"PHASE3","title":"Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2007-01","conditions":"Non Small Cell Lung Cancer, Lung Cancer","enrollment":698},{"nctId":"NCT01876784","phase":"PHASE3","title":"Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2013-09-17","conditions":"Differentiated Thyroid Cancer","enrollment":238},{"nctId":"NCT00537095","phase":"PHASE2","title":"Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2007-09-28","conditions":"Thyroid Neoplasms","enrollment":164},{"nctId":"NCT00098345","phase":"PHASE2","title":"Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2004-11","conditions":"Thyroid Cancer","enrollment":40},{"nctId":"NCT00500292","phase":"PHASE2","title":"A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2007-03","conditions":"Colorectal, Cancer","enrollment":109}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CAPRELSA"],"phase":"phase_3","status":"active","brandName":"Vandetanib (SAR390530)","genericName":"Vandetanib (SAR390530)","companyName":"Genzyme, a Sanofi Company","companyId":"genzyme-a-sanofi-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vandetanib, also known as ZD6474, is a medication used to treat medullary thyroid cancer, specifically locally advanced or metastatic medullary thyroid cancer. It has also been studied in clinical trials for other conditions, including colorectal cancer and thyroid neoplasms.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}